X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences

BOSTON, May 17, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit and present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit.

Details are as follows:

Conference: Cowen 2nd Annual Virtual Oncology Innovation Summit Date: Thursday, May 20, 2021Time: 2:00 PM ET

Conference: Oppenheimer Rare & Orphan Disease SummitDate: Friday, May 21, 2021Time: 12:25 PM ETPresentation Webcast Link

A live webcast of the Oppenheimer Rare & Orphan Disease Summit presentation will be available on the investor section of the X4 Pharmaceuticals website at www.x4pharma.com. Following the live webcast, the event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.

About X4 PharmaceuticalsX4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: Daniel FerryManaging Director LifeSci Advisors[email protected](617) 430-7576

Mónica Rouco MolinaSenior Account Executive LifeSci Communications[email protected]

You May Also Be Interested In

• Educational Analysis Highlights Why Funding Payments Can Move Liquidation Prices Without Market Price Movement
• UPAY Inc. Subsidiary AML GO (Pty) Ltd Appoints Marina Short as Chief Executive Officer
• Graebel and NBCUniversal Recognized with Silver Brandon Hall Group™ Award for Excellence in Talent Management